Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Andrologia ; 48(2): 177-88, 2016 Mar.
Article in English | MEDLINE | ID: mdl-25929857

ABSTRACT

The aim of this study was to investigate the effect of etodolac hydrazone (EH), a new compound synthesised from etodolac, on spermatozoon quality, testicular lipid peroxidation, apoptosis and spermatozoon DNA integrity in rats. Group 1 (n = 8) received 1 ml dimethyl sulfoxide (DMSO) daily (Control); group 2 (n = 8) was treated with 5 mg kg(-1)  day(-1) EH, dissolved in 1 ml DMSO (EH-5); and group 3 (n = 8) was treated with 10 mg kg(-1)  day(-1) EH, dissolved in 1 ml DMSO (EH-10). All administrations were performed by gavage and maintained for 8 weeks. Both doses of EH administration caused significant decreases in absolute and relative weights of testis, whole epididymis, right cauda epididymis, and spermatozoon motility, spermatozoon count in comparison with the control group. Only 10 mg kg(-1)  day(-1) EH administration caused significant decreases in absolute and relative weights of seminal vesicles and serum testosterone level, and significant increases in testicular lipid peroxidation level, and numbers of TUNEL+ apoptotic germ cells and spermatozoa with damaged DNA along with some histopathological damages when compared to the control group. However, body and ventral prostate weight, and testicular antioxidant markers (glutathione, glutathione-peroxidase and catalase), were unaffected significantly by both doses of EH administration. In conclusion, two different doses of EH, in particular its high dose, damage to testicular spermatogenic cells and spermatozoon DNA and, it decreases spermatozoon motility, count and testosterone level in healthy rats.


Subject(s)
Apoptosis/drug effects , Cyclooxygenase 2 Inhibitors/pharmacology , DNA Damage/drug effects , Etodolac/analogs & derivatives , Etodolac/pharmacology , Hydrazones/pharmacology , Lipid Peroxidation/drug effects , Spermatozoa/drug effects , Testis/drug effects , Animals , Catalase/drug effects , Catalase/metabolism , Epididymis/drug effects , Epididymis/pathology , Glutathione/drug effects , Glutathione/metabolism , Glutathione Peroxidase/drug effects , Glutathione Peroxidase/metabolism , In Situ Nick-End Labeling , Male , Organ Size , Rats , Seminal Vesicles/drug effects , Seminal Vesicles/pathology , Sperm Motility/drug effects , Testis/metabolism , Testosterone/blood
2.
J Enzyme Inhib Med Chem ; 30(5): 778-85, 2015.
Article in English | MEDLINE | ID: mdl-25676325

ABSTRACT

Arachidonic acid is an unsaturated fatty acid liberated from phospholipids of cell membranes. NSAIDs are known as targets of cyclooxygenase enzyme (COX-1, COX-2 and COX-3) in arachidonic acid metabolism. This mechanism of COX-2 in carcinogenesis causes cancer. In addition, COX-2 plays a role in the early stages of hepatocarcinogenesis. Hepatitis C virus (HCV) infection is cause of liver cirrhosis and hepatocellular carcinoma (HCC). The aim of our study was to improve effective agents against HCV. A novel series of new etodolac 1,2,4-triazoles derivatives (4a-h) have been synthesized and investigated for their activity against HCV NS5B polymerase. Compound 4a was found to be the most active with IC(50) value of 14.8 µM. In accordance with these results, compound 4a was screened for anti-cancer activity on liver cancer cell lines (Huh7, Mahlavu, HepG2, FOCUS). Compound 4a showed anti-cancer activity against Huh7 human hepatoma cell line with IC(50) value of 4.29 µM. Therefore, compound 4a could be considered as a new anti-cancer and anti-HCV lead compound.


Subject(s)
Antineoplastic Agents/pharmacology , Antiviral Agents/pharmacology , Enzyme Inhibitors/pharmacology , Etodolac/analogs & derivatives , Hepacivirus/drug effects , Triazoles/pharmacology , Viral Nonstructural Proteins/antagonists & inhibitors , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Antiviral Agents/chemical synthesis , Antiviral Agents/chemistry , Cell Line, Tumor , Cell Proliferation/drug effects , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Etodolac/chemical synthesis , Etodolac/chemistry , Etodolac/pharmacology , Hepacivirus/enzymology , Humans , Molecular Structure , Structure-Activity Relationship , Triazoles/chemical synthesis , Triazoles/chemistry , Viral Nonstructural Proteins/metabolism
3.
Arch Pharm (Weinheim) ; 346(5): 367-79, 2013 May.
Article in English | MEDLINE | ID: mdl-23609809

ABSTRACT

Etodolac hydrazide and a novel series of etodolac hydrazide-hydrazones 3-15 and etodolac 4-thiazolidinones 16-26 were synthesized in this study. The structures of the new compounds were determined by spectral (FT-IR, (1)H NMR, (13)C NMR, HREI-MS) methods. Some selected compounds were determined at one dose toward the full panel of 60 human cancer cell lines by the National Cancer Institute (NCI, Bethesda, USA). 2-(1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-yl)acetic acid[(4-chlorophenyl)methylene]hydrazide 9 demonstrated the most marked effect on the prostate cancer cell line PC-3, with 58.24% growth inhibition at 10(-5) M (10 µM). Using the MTT colorimetric method, compound 9 was evaluated in vitro against the prostate cell line PC-3 and the rat fibroblast cell line L-929, for cell viability and growth inhibition at different doses. Compound 9 exhibited anticancer activity with an IC(50) value of 54 µM (22.842 µg/mL) against the PC-3 cells and did not display any cytotoxicity toward the L-929 rat fibroblasts, compared to etodolac. In addition, this compound was evaluated for caspase-3 and Bcl-2 activation in the apoptosis pathway, which plays a key role in the treatment of cancer.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Etodolac/analogs & derivatives , Etodolac/pharmacology , Hydrazones/pharmacology , Neoplasms/drug therapy , Animals , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Caspase 3/metabolism , Cell Line , Cell Line, Tumor , Dose-Response Relationship, Drug , Etodolac/chemical synthesis , Etodolac/chemistry , Fibroblasts/drug effects , Fibroblasts/metabolism , Humans , Hydrazones/chemical synthesis , Hydrazones/chemistry , Inhibitory Concentration 50 , Male , Neoplasms/pathology , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/pathology , Proto-Oncogene Proteins c-bcl-2/metabolism , Rats , Spectrum Analysis
4.
Leuk Lymphoma ; 49(8): 1452-62, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18608871

ABSTRACT

Non-steroidal anti-inflammatory drugs (NSAIDs) comprise the group of structurally diverse but similarly acting compounds that are used for relieving signs and symptoms of inflammation, especially in treatment of rheumatic diseases. Recent reports suggested potential association between regular use of NSAIDs and the risk of development of hematological malignancies. However, the data distinctly differ depending on type of NSAID used, period of its administration and type of malignancy. Regular use of aspirin and other NSAIDs was shown to correlate with reduced risk of lymphoid malignancies. Frequent use of aspirin was found to be associated with decreased risk of acute leukemia (AL) development. In contrast, correlation between long-term acetaminophen usage and increased incidence of AL and multiple myeloma (MM) was indicated. On the other hand, NSAIDs were found to exert anti-cancer effects, inhibiting proliferation and invasive growth or inducing cell apoptosis in several tumors, including hematologic malignancies. One of those agents, non-cyclooxygenase 2-inhibiting R-enantiomer of etodolac (SDX-101), exerts cytotoxic effects against chronic lymphocytic leukemia (CLL) and MM cells, and is currently investigated in phase II clinical trial in CLL. The indole-pyran analogue of SDX-101, SDX-308 (CEP-18082), showed more potent cytotoxicity than SDX-101 against MM cells and inhibited osteoclast formation and activity of mature osteoclasts. Thus, SDX-308 may be an ideal agent for bone disease in MM and related diseases. Another analogue of SDX-101, SDX-309, showed also significant anti-tumor activity in first preclinical studies. The potential role of NSAIDs in prevention and treatment of hematologic malignancies is the subject of this review.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Hematologic Neoplasms/prevention & control , Acetaminophen/adverse effects , Aspirin , Etodolac/analogs & derivatives , Hematologic Neoplasms/drug therapy , Heterocyclic Compounds, 3-Ring , Humans
5.
Invest New Drugs ; 25(4): 297-303, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17440681

ABSTRACT

SDX-308 and SDX-309 are potent indole-pyran analogues of SDX-101 (R-etodolac) which has anti-tumour activity unrelated to cyclooxygenase-2 inhibition. Their cytotoxic activity was further studied herein using a well-characterized human tumour cell-line panel containing ten cell lines, as well as in 58 primary tumour cell samples from a variety of diagnoses. The indole-pyran analogues of SDX-101 were in general considerably more active in both cancer cell lines and primary tumour samples. Low cross-reactivity with standard agents was observed, indicating a unique mechanism of action. No apparent influence on efficacy was observed via classical mechanisms of multidrug-resistance. SDX-101 and SDX-309 showed higher relative activity in haematological compared to solid tumour samples, while SDX-308 had pronounced solid-tumour activity. High SDX-308 cytotoxic efficacy was observed in non-small cell lung cancer, renal cancer and ovarian cancer samples, and also in chronic lymphocytic leukaemia. In conclusion, the indole-pyran analogues showed a favourable pharmacological profile and represent a potentially important new class of drugs for cancer treatment.


Subject(s)
Antineoplastic Agents/pharmacology , Etodolac/analogs & derivatives , Etodolac/pharmacology , Heterocyclic Compounds, 3-Ring/pharmacology , Cell Line, Tumor , Drug Screening Assays, Antitumor , Female , Humans
6.
Xenobiotica ; 34(5): 449-61, 2004 May.
Article in English | MEDLINE | ID: mdl-15370961

ABSTRACT

1. In vitro metabolic studies with etodolac were performed. S- and R-etodolac were converted to the acylglucuronide and hydroxylated metabolites by UDP-glucuronosyltransferase (UGT) and cytochrome P450 in microsomes. However, the stereoselectivities of UGT and P450 for the isomers were opposite. S-etodolac was glucuronidated preferentially than R-etodolac by UGT. In contrast, R-etodolac was hydroxylated preferentially than S-etodolac by P450. 2. Of several human P450 enzymes, CYP2C9 had the greatest activity for hydroxylation of R-etodolac. Sulfaphenazole, an inhibitor of CYP2C9, and anti-CYP2C9 antibody inhibited the hydroxylation of R-etodolac in human liver microsomes. CYP2C9 therefore contributes to the stereoselective hydroxylation of R-etodolac. 3. Of several human UGT enzymes, UGT1A9 had the greatest activity for glucuronidation of S-etodolac. Propofol and thyroxine, inhibitors of UGT1A9, inhibited the glucuronidation of S-etodolac in human liver microsomes. Therefore, UGT1A9 is mainly responsible for the stereoselective glucuronidation of S-etodolac. 4. Because S-etodolac was metabolized more rapidly than R-etodolac in human cryopreserved hepatocytes, the stereoselectivities of UGT1A9 for etodolac substantially influenced the overall metabolism of S- and R-etodolac in man.


Subject(s)
Aryl Hydrocarbon Hydroxylases/metabolism , Etodolac/analogs & derivatives , Etodolac/metabolism , Glucuronosyltransferase/metabolism , Animals , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Anti-Inflammatory Agents, Non-Steroidal/metabolism , Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors , Cell Line , Cytochrome P-450 CYP2C9 , Enzyme Inhibitors/pharmacology , Etodolac/chemistry , Glucuronates/chemistry , Glucuronates/metabolism , Glucuronosyltransferase/antagonists & inhibitors , Hepatocytes/metabolism , Humans , Hydroxylation , In Vitro Techniques , Isoenzymes/metabolism , Kinetics , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Propofol/pharmacology , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/metabolism , Stereoisomerism , Sulfaphenazole/pharmacology , Thyroxine/pharmacology
7.
J Pharm Biomed Anal ; 25(5-6): 977-84, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11377082

ABSTRACT

The non-steroidal anti-inflammatory drug etodolac is extensively metabolized in the liver. Renal elimination of etodolac mainly as glucuronide and its other phase I and phase II metabolites is the primary route of excretion. High-performance liquid chromatography assays of human urine after application of etodolac indicated the existence of a further monohydroxylated metabolite (metabolite X) that was identified as 5-hydroxy etodolac. For the identification, electrospray ionization mass spectrometry (ESI-MS) as well as 1H-nuclear magnetic resonance (1H-NMR) and 13C-NMR spectroscopy have been used.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/metabolism , Etodolac/isolation & purification , Etodolac/metabolism , Anti-Inflammatory Agents, Non-Steroidal/urine , Chromatography, High Pressure Liquid , Etodolac/analogs & derivatives , Etodolac/urine , Humans , Magnetic Resonance Spectroscopy , Spectrometry, Mass, Electrospray Ionization
8.
Transfusion ; 40(6): 663-8, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10864985

ABSTRACT

BACKGROUND: Immune hemolytic anemia can be caused by sensitivity to many different drugs. In some instances, the sensitizing compound can be identified by in vitro testing, but results are often negative. One reason for this is that a drug metabolite formed in vivo can be the sensitizing agent, but the responsible metabolites have rarely been identified at a chemical level. This report describes a patient who developed severe, Coombs-positive hemolytic anemia on two occasions after taking the nonsteroidal anti-inflammatory drug etodolac. Studies were performed to characterize etodolac metabolites to which this patient was sensitive. CASE REPORT: Serum was tested for antibody in the presence and absence of drug using conventional methods and urine from individuals taking etodolac as a source of drug metabolites. Urinary metabolites of etodolac were identified by high-pressure liquid chromatography analysis. Glucuronide conjugates of etodolac and the 6-OH metabolite of etodolac were synthesized in a rat liver microsomal system to obtain reference standards. RESULTS: The patient's serum gave only trace (+/-) reactions with normal RBCs in the presence of etodolac but reacted strongly (4+) in the presence of urine from an individual taking this drug. The active urinary metabolites were identified as etodolac glucuronide and 6-OH etodolac glucuronide. CONCLUSION: This patient appears to have experienced acute, severe immune hemolytic anemia on two occasions because of sensitivity to the glucuronides of etodolac and 6-OH etodolac. In patients suspected of having drug-induced immune hemolytic anemia, RBC-reactive antibodies can sometimes be detected by using urine from an individual taking the implicated medication as the source of drug metabolites in in vitro reactions. For patients who present with acute immune hemolysis, a careful history of drug exposure should be taken, and, where indicated, confirmatory testing should be performed to identify the sensitizing drug and prevent inadvertent reinduction of hemolysis at a later time.


Subject(s)
Anemia, Hemolytic, Autoimmune/chemically induced , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Autoimmune Diseases/chemically induced , Drug Hypersensitivity/etiology , Etodolac/analogs & derivatives , Etodolac/adverse effects , Glucuronates/adverse effects , Acute Disease , Adult , Anemia, Hemolytic, Autoimmune/immunology , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Autoimmune Diseases/immunology , Chromatography, High Pressure Liquid , Coombs Test , Drug Hypersensitivity/immunology , Etodolac/pharmacokinetics , Female , Humans , Low Back Pain/drug therapy , Microsomes, Liver/metabolism , Molecular Structure , Rats , Recurrence
SELECTION OF CITATIONS
SEARCH DETAIL
...